Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

Breast Cancer Research and Treatment

Volumn 113, Issue 3, 2009, Pages 491-499

  Jannuzzo, Maria Gabriella ^a   Di Salle, Enrico ^b   Spinelli, Riccardo ^a   Pirotta, Nicoletta ^a   Buchan, Peter ^a   Bello, Akintunde ^b  

^a NERVIANO MEDICAL SCIENCES   (Italy)

^b PFIZER INC   (United States)

Author keywords

Aromatase inhibitors; Exemestane; Gonadotropin releasing hormone agonists; Pharmacokinetics; Premenopausal healthy volunteers; Triptorelin

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTRONE; EXEMESTANE; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; LUTEINIZING HORMONE; TRIPTORELIN;

ABDOMINAL PAIN; ACNE; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BREAKTHROUGH BLEEDING; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; FATIGUE; FEMALE; FIBROCYSTIC BREAST DISEASE; HEADACHE; HEART PALPITATION; HORMONE INHIBITION; HOT FLUSH; HUMAN; LOOSE FECES; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL CYCLE; MULTICENTER STUDY; NAUSEA; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VAGINA BLEEDING; VOMITING;

ADULT; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTRADIOL; ESTRONE; FEMALE; GONADOTROPINS; HUMANS; OVARY; PREMENOPAUSE; TRIPTORELIN; YOUNG ADULT;

EID: 58549110458     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9949-9     Document Type: Article

References (26)

1. JG Klijn RW Blamey F Boccardo 2001 Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials J Clin Oncol 19 343 353
2. DC Johannessen T Engan E Di Salle 1997 Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study Clin Cancer Res 3 1101 1108
3. J Geisler B Haynes G Anker M Dowsett PE Lonning 2002 Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 751 757
4. J Geisler N King G Anker 1998 In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients Clin Cancer Res 4 2089 2093
5. RW Brueggemeier JC Hackett ES Diaz-Cruz 2005 Aromatase inhibitors in the treatment of breast cancer Endocr Rev 26 331 345
6. WR Miller 2004 Biological rationale for endocrine therapy in breast cancer Best Pract Res Clin Endocrinol Metab 18 1 32
7. P Lonning C Pfister A Martoni C Zamagni 2003 Pharmacokinetics of third-generation aromatase inhibitors Semin Oncol 30 23 32
8. M Kaufmann E Bajetta LY Dirix 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group J Clin Oncol 18 1399 1411
9. ® (exemestane) (2005) Full prescribing information. Pharmacia & Upjohn Co, Division of Pfizer Inc., New York, NY
10. M Filicori C Flamigni G Cognigni 1993 Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women J Clin Endocrinol Metab 77 130 133
11. Bolton S (1990) Pharmaceutical statistics: practical and clinical applications, 2nd edn. Marcel Dekker Inc., New York, NY
12. LB Michaud KL Jones AU Buzdar 2001 Combination endocrine therapy in the management of breast cancer Oncologist 6 538 546
13. A Rody S Loibl G von Minckwitz M Kaufmann 2005 Use of goserelin in the treatment of breast cancer Expert Rev Anticancer Ther 5 591 604
14. M Dowsett E Folkerd D Doody B Haynes 2005 The biology of steroid hormones and endocrine treatment of breast cancer Breast 14 452 457
15. IE Smith M Dowsett YS Yap 2006 Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines J Clin Oncol 24 2444 2447
16. National Comprehensive Cancer Network (2007) Clinical practice guidelines in oncology: breast cancer, Version 2, 2007. http://www.nccn.org/professionals/ physician-gls/PDF/breast.pdf. Cited July 26, 2007
17. L Celio A Martinetti L Ferrari 1999 Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study Anticancer Res 19 2261 2268
18. M Dowsett D Doody S Miall 1999 Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer Breast Cancer Res Treat 56 25 34
19. DP Forward KL Cheung L Jackson JF Robertson 2004 Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer Br J Cancer 90 590 594
20. D Clemett HM Lamb 2000 Exemestane: a review of its use in postmenopausal women with advanced breast cancer Drugs 59 1279 1296
21. M Dank 2002 The role of aromasin in the hormonal therapy of breast cancer Pathol Oncol Res 8 87 92
22. RC Coombes E Hall LJ Gibson 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092
23. R Paridaens L Dirix C Lohrisch 2003 Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer Ann Oncol 14 1391 1398
24. ® Depot (triptorelin pamoate for injectable suspension) (2006) Full prescribing information. Watson Pharma, Inc., Corona, CA
25. S Dellapasqua M Colleoni RD Gelber A Goldhirsch 2005 Adjuvant endocrine therapy for premenopausal women with early breast cancer J Clin Oncol 23 1736 1750
26. EP Winer C Hudis HJ Burstein 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004 J Clin Oncol 23 619 629